Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: A 5-year follow-up of a single-center cohort

Clinical Rheumatology

Volumn 33, Issue 2, 2014, Pages 197-205

  Költő, Gyöngyvér ^a   Faludi, Réka ^b   Aradi, Dániel ^b   Bartos, Barbara ^b   Kumánovics, Gábor ^b   Minier, Tünde ^b   Czirják, László ^b   Komócsi, András ^b  

^a Kaposi Mor Teaching Hospital   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Microvascular disease; Pulmonary hypertension; Scleroderma; Survival

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY PRESSURE; DIABETES MELLITUS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART DISEASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; TRICUSPID VALVE REGURGITATION;

AGED; CARDIAC CATHETERIZATION; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SCLERODERMA, SYSTEMIC;

EID: 84893949782     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2358-4     Document Type: Article

References (35)

1. Komocsi A, Vorobcsuk A, Faludi R et al (2012) The impact of cardio-pulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 51:1027-1036
2. Czirjak L, Pakozdi A, Kumanovics G et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67:59-63
3. Trad S, Amoura Z, Beigelman C et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184-191
4. Komocsi A, Pinter T, Faludi R et al (2010) Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 69:202-205
5. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
6. Hatano S and Strasser T (1975) Primary pulmonary hypertension: report on a WHO meeting, Geneva, 15-17 October 1973
7. Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54
8. Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537
9. Kern MJ (2000) Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. Circulation 101:1344-1351
10. Meune C, Vignaux O, Kahan A, Allanore Y (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103:46-52
11. Kahan A, Nitenberg A, Foult JM et al (1985) Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 28:637-646
12. Pinter T, Faludi R, Magyari B et al (2011) Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology (Oxford) 50:781-788
13. Pinter T, Faludi R, Magyari B et al (2010) Mechanism of coronary flow reserve reduction in systemic sclerosis, insight from intracoronary pressure-wire studies. Rheumatology (Oxford). doi: 10.1093/rheumatology/keq402
14. Steen VD, Follansbee WP, Conte CG, Medsger TA Jr (1996) Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 39:677-681
15. Kahan A, Devaux JY, Amor B et al (1990) The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 47:483-489
16. Kahan A, Devaux JY, Amor B et al (1986) Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis 45:718-725
17. Kahan A, Devaux JY, Amor B et al (1986) Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 314:1397-1402
18. Allanore Y, Meune C, Vignaux O et al (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol 33:2464-2469
19. Allanore Y, Meune C, Vonk MC et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69:218-221
20. Caiati C, Montaldo C, Zedda N et al (1999) Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. J Am Coll Cardiol 34:1193-1200
21. Hachulla AL, Launay D, Gaxotte V et al (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 68:1878-1884
22. Allanore Y, Wahbi K, Borderie D et al (2009) N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 68:1885-1889
23. Au K, Singh MK, Bodukam V et al (2011) Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum 63:2078-2090
24. Poms AM, Turner M, Farber HW, Meltzer LA, and McGoon MD (2013) Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest
25. Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33:1635-1701
26. Hachulla E, Gressin V, Guillevin L et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792-3800
27. McGoon M, Gutterman D, Steen V et al (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126:14S-34S
28. Humbert M, Yaici A, de Groote P et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:3522-3530
29. Kovacs G, Maier R, Aberer E et al (2012) Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 64:1257-1262
30. Avouac J, Wipff J, Kahan A, Allanore Y (2008) Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 67:808-814
31. Ryerson CJ, Nayar S, Swiston JR, Sin DD (2010) Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 11:12
32. Galie N, Manes A, Negro L et al (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394-403
33. Williams MH, Das C, Handler CE et al (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926-932
34. Hachulla E, Carpentier P, Gressin V et al (2009) Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 48:304-308
35. Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55-S66